From April 1, 2023 to June 30, 2023, the company has repurchased 368,809 shares, representing 1.2% for $0.56 million. With this, the company has completed the repurchase of 4,559,479 shares, representing 13.81% for $15.26 million under the buyback announced on March 15, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.23 USD | -7.52% | -14.48% | -6.77% |
06-14 | Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform | CI |
05-13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.77% | 41.6M | |
-34.99% | 14.88B | |
-54.45% | 2.26B | |
+16.54% | 1.89B | |
-11.85% | 1.52B | |
+19.90% | 1.19B | |
-29.99% | 871M | |
+2.21% | 781M | |
-35.68% | 750M | |
-29.02% | 591M |
- Stock Market
- Equities
- CODX Stock
- News Co-Diagnostics, Inc.
- Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.